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Key points
•  Significantly lower BMD in PD compared to healthy subjects in both genders.
•  Less than 35 mg2/dl2 of Ca–P product in >80% of PD patients.
•  Significant correlations between BMD and severity of PD.
•  Lower BMD at H&Y stage III/IV than that at H&Y stage I/II.
Objectives:  Although  several  lines  of  evidence  have  suggested  that  patients  with 
Parkinson’s disease (PD) have a higher risk of osteoporosis and fracture, the association 
between bone mineral density (BMD) and severity of PD patients is unknown.
Methods: We performed a cross-sectional study of 54 patients with PD and 59 healthy 
age-matched controls. Multiple clinical scales were used to evaluate the severity of PD, 
and serum levels of calcium, phosphorus, and homocysteine were measured to deter-
mine BMD’s association with PD severity.
results: BMD in PD patients was significantly lower than that in healthy controls. The 
BMD scores of the spine, femoral neck (FN), and hip were lower in females than in males 
in the healthy group. In the PD group, BMD in the hip was significantly lower in females 
compared to males. There was a negative correlation between daily l-DOPA dosage and 
BMD in the spine and hip in the PD group, while BMD in the spine, neck, and hip was 
significantly correlated with severity of PD. Besides, we found that among the  lumbar 
spine (LS), FN, and hip, bone loss in the LS was the most severe in PD patients based 
on the T-scores.
conclusion: Our findings support the hypothesis that patients with PD have a higher 
risk of osteoporosis, and that low BMD in the spine, FN, and hip may indirectly reflect the 
severity of PD. Our findings have prompted us to pay more attention to osteoporosis in 
the LS in Chinese PD patients.
Keywords: Parkinson’s disease, bone mineral density, motor symptoms, levodopa, osteoporosis
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inTrODUcTiOn
Parkinson’s disease (PD) is typically characterized by motor 
symptoms (MS) and non-motor symptoms (NMS). All of the 
MS and NMS damage the quality of daily life (Bryant et  al., 
2015). Among the NMS, osteoporosis, a metabolic skeletal dis-
order characterized by low bone mass and the microarchitectural 
deterioration of bone tissue in aged subjects, affects a majority 
of PD patients. Osteoporosis is recognized as a dysfunction in 
terms of microarchitectural deterioration and low bone mass 
[T-score: <−2.5 standard deviations (SDs)], which increases 
skeletal fragility (Kanis, 2002; Kanis et al., 2008). It has been well 
documented that both calcium and phosphorus play key roles 
in the formation of new bone and in the maintenance of exist-
ing bone (Hong et al., 2013). An increase in the ratio of serum 
calcium concentration and phosphorus concentration (Ca/P) 
significantly decreases the risk for osteoporosis (Hong et  al., 
2013). It has been reported that older females are susceptible 
to osteoporosis due to their decreased levels of estrogen (Tyagi 
et al., 2012; Cui et al., 2013). On the other hand, numerous studies 
have indicated that fracture-related morbidity and mortality are 
higher in older men than in women, and osteoporotic fractures 
usually occur at approximately 70–75  years old (Gielen et  al., 
2011). Currently, several epidemiological studies have confirmed 
that bone mineral density (BMD) is the single best predictor of 
future fracture (Cooper and Melton Iii, 1992; Allen et al., 2012). 
Although there were previous studies showing the BMD changes 
in PD patients, most of these studies were undertook in Western 
countries and some Asian countries such as Japan and Korea. 
There is no study yet from Chinese population. Since there are 
huge differences in ethnicity, food, and life habit between Chinese 
and Westerners and among Asia populations such as Japanese, it 
is necessary to determine if there are any specific changes in BMD 
of Chinese PD patients as compare to that in other countries.
Patients with PD have a higher risk of fallings, osteoporosis, 
and fracture (Genever et al., 2005; Fink et al., 2008; Abou-Raya 
et al., 2009). Several lines of evidence suggest that patients with 
PD fall frequently compared to healthy subjects (Gazibara et al., 
2015). The factors that affect the likelihood of falling in PD patients 
can be divided into two categories: PD-related and PD-unrelated 
(e.g., age-related falling and fracture) factors. The PD-related 
factors include poor balance, freezing of gait, poor lower extrem-
ity sensation and lower extremity weakness, depression, and the 
severity of the disease. Homocysteine (Hcy) levels have recently 
attracted wide clinical attention as a predictor of PD progression. 
Elevated plasma levels of Hcy have been observed in PD patients 
(Zhang et  al., 2011), and Hcy is known to participate in bone 
remodeling (Vacek et al., 2013). However, it remains unknown if 
serum Hcy is correlated with severity of PD.
We undertook this study to determine whether BMD could 
predict or evaluate the outcomes of motor/non-motor status in 
patients with PD. The primary goal of this study was to compare 
the levels of different clinical parameters between PD and healthy 
subjects. The second aim was to assess whether gender plays 
an important role in the pathogenesis of bone loss and bone 
osteoporosis in PD patients. The third purpose of this study was 
to conduct an exploratory analysis to identify any association 
between BMD and PD progression, especially with respect to 
poor motor function and l-DOPA dosage and any association 
between BMD and Hoehn and Yahr stages (H&Y).
MaTerials anD MeThODs
Patients, ethics statement, and  
study Design
From July 2011 to September 2015, a total of 54 patients with PD 
(Table 1) who were admitted to the Department of Neurology 
of the Third Affiliated Hospital of Sun Yat-sen University, 
Guangzhou, P. R. China were enrolled in this cross-sectional 
study. The patients were identified according to the United 
Kingdom IPD Society Brain Bank (UK-PDSBB) criteria (Hughes 
et al., 1992). In addition, 59 healthy control subjects matched for 
age and sex were recruited from the outpatient population as the 
control group. PD patients were excluded if they had other known 
causes of osteoporosis, cerebrovascular disease, renal, hepatic or 
thyroid impairment, or a history of therapy with corticosteroids, 
TaBle 1 | Demographic, motor, and non-motor parameters  
of PD patients.
clinical parameters PD
Mean (±sD) Min Max
Gender (n)
  Male (%) 29 (53.7)
  Female (%) 25 (46.3)
Age (years) 65.00 (9.00) 48 80
Disease duration (years) 3.99 (2.88) 1 10
BMI 21.88 (2.95) 16.00 29.82
Daily l-DOPA dosage (mg) 377.54 (129.76) 100 700
Webster 8.01 (3.43) 4 18
S&E (%) 76.68 (13.17) 50 90
H&Y 2.11 (0.816) 1 4
UPDRS II 18.22 (5.40) 6 27
UPDRS III 21.42 (11.89) 11 33
Ca (mg/dl) 2.352 (0.14) 2.1 2.7
P (mg/dl) 1.043 (0.15) 0.77 1.39
Ca*P (mg2/dl2) 31.32 (4.54) 22.84 43.52
Ca–P product <35 (mg2/dl2) n (%) 45 (83.3)
Ca–P product ≥35 (mg2/dl2) n (%) 9 (16.7)
Hcy (μmol/l) 13.49 (4.79) 5.44 35.02
BMI, body mass index; Ca, calcium; Ca*P, serum Ca concentration and phosphorus 
concentration product; Hcy, homocysteine; H&Y, the modified Hoehn and Yahr staging 
scale; l-DOPA, levodopa; P, phosphorus; PD, Parkinson’s disease; UPDRS, unified 
Parkinson’s disease rating scale.
Abbreviations: BMD, bone mineral density; BMI, body mass index; Ca, calcium; 
Ca–P product, serum calcium concentration and phosphorus concentration 
product; DXA, dual-energy X-ray absorptiometry; FN, femoral neck; Hcy, homo-
cysteine; H&Y, Hoehn and Yahr staging scale; l-DOPA, levodopa; LS, lumbar 
spine; LSC, least significant change; MMPs, matrix metalloproteinases; MS, motor 
symptoms; NMS, non-motor symptoms; P, phosphorus; PD, Parkinson’s disease; 
PTH, parathyroid hormone; RBD, rapid eye movement sleep; rs, the Spearman’s 
rank correlation coefficient; SD, standard deviation; S&E, the Schwab & England 
activities of daily living scale; UK-PDSBB, the United Kingdom IPD Society Brain 
Bank; UPDRS, unified Parkinson’s disease rating scale; 25-OHDA, 25-hydroxyvi-
tamin D; 1,25-[OH](2)D, 1,25-dihydroxyvitamin D.
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estrogen, bisphosphonates, calcitonin, calcium, or vitamin D. 
The study was approved by the local Ethics Committee of the 
Third Affiliated Hospital of Sun Yat-sen University and con-
ducted according to the principles outlined in the Declaration of 
Helsinki of 1975. All of the participants provided written consent 
for the investigation and for the measurements using the unified 
Parkinson’s disease rating scale (UPDRS), the Schwab & England 
activities of daily living scale (S&E), the Webster scale, and the 
H&Y scale (Hoehn and Yahr, 1967). The demographics and clini-
cal data of the subjects are shown in Table 1.
Blood sampling Measurement
Venous blood samples were collected in the early morning under 
fasting condition in order to obtain serum Ca, P, and plasma Hcy 
measurements in the study. Concentrations of Ca and P were 
ascertained according to certified methods of the Institute of 
Clinical Chemistry and Laboratory Medicine, the Third Affiliated 
Hospital of Sun Yat-Sen University. For Hcy measurement, the 
blood samples were centrifuged at 3,000 rpm for 10 min and stored 
at −70° C until the laboratory evaluation. The plasma levels of Hcy 
were determined using a solid phase competitive chemilumines-
cent enzyme immunoassay (Rodriguez-Oroz et al., 2009; Zhang 
et al., 2011). All of blood measurements were replicated thrice.
Bone Mineral Density Measurement
Bone mineral density (g/cm2) of the lumbar spine (LS), 
femoral neck (FN), and hip were measured using a dual-energy 
X-ray absorptiometry (DXA) machine (model, Discovery A) 
according to the manufacturer’s guidelines (Kanis, 2002; Wood 
and Walker, 2005; Kanis et  al., 2008). Before measurement, 
routine quality control was performed to make sure our device 
was accurate and all the subjects underwent the measurement 
after bladder emptying. The least significant change (LSC) at 
our department was calculated to be 0.041 (LS), 0.042 (hip), and 
0.035 g/cm2 (FN), within the limits of International Society for 
Clinical Densitometry (Xie et al., 2013). Z- and T-scores were 
automatically calculated by the software in the work station 
of DXA, where the Z-score is the SD of the individual’s BMD 
compared to the mean BMD score of a similar sex- and age-
matched population, and the T-score is the SD of the individual’s 
BMD compared with the mean BMD score of a young, healthy 
population. For menopausal women and men over 50 years old, 
BMD was categorized as normal, osteopenia (low bone density) 
or osteoporosis, as defined by the World Health Organization 
(WHO) (Gielen et al., 2011). A typical BMD image of the PD 
patients is shown in Figure 1.
statistical analysis
All continuous variables, including age, disease duration, body 
mass index (BMI), Webster, S&E, UPDRS II, and UPDRS III 
scores, H&Y stage, and Ca, P, Ca*P, and Hcy levels, were pre-
sented as the mean ± SD, and all categorical variables, including 
gender, Ca–P product <35 (mg2/dl2), and Ca–P product ≥35 
(mg2/dl2) were presented as numbers and percentages. The statis-
tical significance of differences between the groups was assessed 
using Student’s t-test. And gender difference in affecting BMD in 
FigUre 1 | Dual-energy X-ray absorptiometry (DXa) imaging of BMD in a male PD patient: (a) the whole body, (B) spine, and (c) left hip. (a–c) The 
patients’ BMD vs. a male Chinese control of the whole body (a), spine (b), and left hip (c). In (a–c), the first cure line stands for baseline in the different ages; the 
second cure line stands for the boundary between normal BMD and osteopenia; the third cure line stands for the boundary between osteopenia and osteoporosis, 
and the round dot stands for the patients’ BMD.
TaBle 4 | gender differences in bone mineral density in PD patients vs. 
healthy subjects.
p PD: male vs. 
female
con: male vs. 
female
Male: PD 
vs. con
Female: PD 
vs. con
Age 0.318 0.607 0.844 0.486
BMI 0.624 0.964 0.024* 0.069
Height 0.000*** 0.000*** 0.271 0.750
Weight 0.078 0.005** 0.034* 0.071
LS 0.192 0.005** 0.000** 0.002**
LS T-score 0.918 0.053 0.000** 0.001**
LS Z-score 0.003** 0.599 0.000** 0.000***
FN 0.094 0.003** 0.008** 0.012*
FN T-score 0.430 0.261 0.012* 0.009**
FN Z-score 0.491 0.670 0.001** 0.002**
Hip 0.007** 0.001** 0.007** 0.009**
Hip T-score 0.382 0.229 0.005** 0.005**
Hip Z-score 0.069 0.202 0.002** 0.001**
Two-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001 with two-way ANOVA.
TaBle 3 | Demographic data and bone mineral density of PD patients: 
gender differences.
subjects PD  
male (sD)
PD  
female (sD)
con  
male (sD)
con  
female (sD)
Age 66.19 (9.29) 63.62 (8.76) 66.71 (9.18) 65.36 (9.71)
BMI 21.65 (2.52) 22.11 (3.38) 23.96 (3.43) 24.00 (3.60)
Height 165.61 (3.91) 157.56 (6.61) 167.84 (7.65) 157.03 (5.20)
Weight 59.44 (7.74) 54.75 (7.77) 68.16 (15.16) 59.05 (8.24)
LS 0.82 (0.11) 0.77 (0.12) 1.00 (0.16) 0.88 (0.13)
LS 
T-score
−2.43 (1.08) −2.46 (1.05) −0.74 (1.38) −1.43 (1.25)
LS 
Z-score
−1.66 (0.98) −0.77 (1.02) 0.16 (1.35) 0.34 (1.14)
FN 0.70 (0.12) 0.64 (0.11) 0.79 (0.12) 0.71 (0.08)
FN 
T-score
−1.69 (0.91) −1.90 (1.00) −1.0 (0.85) −1.26 (0.80)
FN 
Z-score
−0.59 (0.80) −0.42 (0.94) 0.21 (0.79) 0.30 (0.71)
Hip 0.87 (0.11) 0.79 (0.10) 0.97 (0.15) 0.85 (0.09)
Hip 
T-score
−1.10 (0.70) −1.29 (0.84) −0.40 (0.95) −0.68 (0.76)
Hip 
Z-score
−0.46 (0.68) −0.10(0.72) 0.31 (0.92) 0.58(0.69)
TaBle 2 | comparison of bone mineral density between PD patients and 
healthy subjects.
PD control p
Mean (sD) Mean (sD)
Age 65.00 (9.00) 65.85 (9.46) 0.632
Height 161.58 (6.73) 161.01 (8.09) 0.725
Weight 57.10 (8.01) 62.41 (12.01) 0.021
BMI 21.90 (2.90) 23.99 (3.51) 0.004**
LS (g/cm2) 0.80 (0.11) 0.93 (0.15) 0.000***
LS T −2.44 (1.06) −1.17 (1.29) 0.000***
LS Z −1.25 (1.08) 0.27(1.21) 0.000***
FN (g/cm2) 0.67 (0.12) 0.74 (0.11) 0.002**
FN T −1.78 (0.95) −1.12 (0.82) 0.000***
FN Z −0.51 (0.86) 0.26 (0.74) 0.000***
Hip (g/cm2) 0.83(0.11) 0.90 (0.13) 0.004**
Hip T −1.19 (0.76) −0.57 (0.84) 0.000***
Hip Z −0.29 (0.71) 0.48 (0.78) 0.000***
*p < 0.05, **p < 0.01, ***p < 0.001 with Student’s test.
October 2015 | Volume 7 | Article 2034
Gao et al. Bone mineral density and PD
Frontiers in Aging Neuroscience | www.frontiersin.org
PD was assessed employing two-way ANOVA. Spearman’s rank 
correlation coefficient (rs) was used to evaluate the correlations 
of the different clinical parameters. A p-value <0.05 was deemed 
statistically significant, and SPSS 13.0 software (Chicago, IL, 
USA) was used for the statistical analyses.
resUlTs
Patient characteristics
The cross-sectional study consisted of 54 PD patients [29 males 
(53.7%) and 25 females (46.3%)] and 59 healthy subjects [34 
males (57.6%) and 25 females (42.4%)] (Tables 1 and 2). Detailed 
information was shown in Tables 2–4.
comparisons of Bone Mineral Density 
Between the PD Patients and the normal 
subjects
No significant difference in age, height, or weight was observed 
between the PD patients and the healthy controls (Table  2) 
in this study. However, a significant difference in BMI was 
observed between the PD patients and the healthy controls 
(**p = 0.004; Table 2). Moreover, the LS BMD in the PD patients 
was remarkably lower than that in the controls (***p < 0.001, 
Table  2). Accordingly, the T-scores and Z-scores for the LS 
BMD were decreased in the PD patients compared with those 
in the healthy subjects (Table 2). Furthermore, similar differ-
ences were found in the FN and hip between the PD patients 
and the matched controls. The FN BMD in the PD patients was 
0.67 ± 0.12 g/cm2, while it was 0.74 ± 0.11 g/cm2 in the control 
group. The hip BMD was 0.83 ±  0.11 vs. 0.90 ±  0.13  g/cm2, 
*p =  0.004 (Table  2; Figure 2A). The results of the compari-
sons of the T-scores and Z-scores for the FN were as follows: 
T-score, −1.78 ± 0.95 vs. −1.12 ± 0.82, ***p < 0.001; Z-score, 
−0.51 ± 0.86 vs. 0.26 ± 0.74, ***p < 0.001; and for the hip were: 
T-score, −1.19 ± 0.76 vs. −0.57 ± 0.84, ***p < 0.001; Z-score, 
−0.29 ± 0.71 vs. 0.48 ± 0.78, ***p < 0.001 (Table 2). Moreover, 
among the LS, FN, and hip, bone loss in the LS was the most 
serious in PD patients based on the T-scores.
gender Differences in affecting  
BMD in PD
Because gender is one of the factors that influences BMD, we 
further analyzed BMD in the different genders. Our results 
showed that significant differences were observed in the BMD of 
the LS, FN, and hip between healthy males and healthy females 
(Tables 3 and 4). Significant differences were observed for BMI, 
height, LS Z-score, and hip BMD when comparing male PD 
patients with female PD patients (Tables 3 and 4). Significant 
differences were found between the male PD patients and the 
male healthy controls in terms of BMI (*p =  0.024), weight 
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(*p = 0.034), LS BMD (***p < 0.001), LS T-score (***p < 0.001), 
LS Z-score (***p < 0.001), FN BMD (**p = 0.008), FN T-score 
(*p = 0.012), FN Z-score (**p = 0.001), hip BMD (**p = 0.007), 
hip T-score (**p  =  0.005), and hip Z-score (**p  =  0.002) 
(Table 4). In the female PD and healthy cohorts, there were also 
significant differences in the LS BMD (**p = 0.002), LS T-score 
(**p = 0.001), LS Z-score (***p < 0.001), FN BMD (**p = 0.012), 
FN T-score (**p  =  0.009), FN Z-score (**p  =  0.002), and 
hip BMD (**p  =  0.009), LS T-score (**p  =  0.005), Z-score 
(**p = 0.001) (Figure 2B).
correlations Between BMD and age, 
l-DOPa Dose, s&e, Webster, UPDrs ii, 
and UPDrs iii scores as Well as  
h&Y stage
There were significant negative correlations between age and LS 
BMD (rs = −0.195, *p = 0.044), T-score (rs = −0.202, *p = 0.037), 
FN BMD (rs = −0.226, *p =  0.019), FN T-score (rs = −0.249, 
*p = 0.010), hip BMD (rs = −0.153, *p = 0.029), and hip T-score 
(rs = −0.217, *p = 0.025) (Table 5). This means that in the PD 
patients, BMD decreased as age increased. Significant negative 
correlations were also found between daily l-DOPA dosage 
and LS BMD (rs = −0.443, *p = 0.019), LS T-score (rs = −0.388, 
*p = 0.033), hip BMD (rs = −0.422, *p = 0.023), and hip T-score 
(rs  =  0.372, *p  =  0.038) (Table  5). We observed significant 
negative correlations between BMD (T-score and Z-score) and 
FigUre 2 | BMD in PD patients and healthy controls. (a) Comparison of BMD in the lumbar spine (LS), femoral neck (FN), and hip between the matched 
control group and the PD group. There are significant differences in LS, FN, and hip BMD between the PD patients and the controls. *LS: PD vs. control:  
0.80 ± 0.11 vs. 0.93 ± 0.15, ***p < 0.001; #FN: PD vs. control: 0.67 ± 0.12 vs. 0.74 ± 0.11, **p = 0.002; and hip: PD vs. control: 0.83 ± 0.11 vs. 0.90 ± 0.13,  
**p = 0.004. (B) Comparison of BMD in the lumbar spine (LS), femoral neck (FN), and hip between the matched control group and the PD group, which were 
divided into gender-specific groups. There are significant differences in LS BMD between the control males and the control females (▫: 1.00 ± 0.16 vs. 0.88 ± 0.13, 
**p = 0.005), the PD males and the control males (▫: 0.82 ± 0.11 vs. 1.00 ± 0.16, ***p < 0.001), and the PD females and the control females (⚬: 0.77 ± 0.12  
vs.0.88 ± 0.13, **p = 0.002). There are significant differences in FN BMD between the control males and the control females (∙: 0.79 ± 0.12 vs. 0.71 ± 0.08,  
**p = 0.003), the PD males and the control males (▫: 0.70 ± 0.12 vs. 0.79 ± 0.12, **p = 0.008), and the PD females and control females (▫: 0.64 ± 0.11  
vs. 0.71 ± 0.08, *p = 0.012). There are significant differences in hip BMD between the PD males and PD females (▫: 0.87 ± 0.11 vs. 0.79 ± 0.10, **p = 0.007), the 
control males and the control females (▫: 0.97 ± 0.15 vs. 0.85 ± 0.09, **p = 0.001), the PD males and the control males (▵: 0.87 ± 0.11 vs. 0.97 ± 0.15,  
**p = 0.007), and the PD females and the control females (▵: 0.79 ± 0.10 vs. 0.85 ± 0.09, **p = 0.009).
Webster, UPDRS II, and UPDRS III scores as well as H&Y stage, 
and a positive correlation between BMD and S&E score, with no 
significant correlations between LS BMD and UPDRS II score 
(p = 0.090). Therefore, our data show that disease severity was 
increased in the patients who experienced greater bone loss.
Different changes in Bone Mineral Density 
in the PD Patients at Different h&Y stages
To explore the relationship between BMD and the severity of MS 
in different stages of PD, the patients were categorized into two 
groups according to the H&Y scale: group one for H&Y I and 
II and group two for H&Y III and IV. A significant difference 
was observed between the two groups in BMD, including LS 
BMD, **p = 0.005, T-score of spine, **p = 0.003; Z-score of spine, 
** p = 0.002; FN BMD, *p = 0.027; T-score of FN, *p = 0.015; 
Z-score of FN, **p = 0.007, hip BMD, **p = 0.004; T-score of hip, 
***p < 0.001; and Z-score of hip, **p = 0.001 (Table 6).
DiscUssiOn
Previous studies have indicated BMD changes in PD patients 
(Genever et al., 2005; Di Monaco et al., 2006; Abou-Raya et al., 
2009; Song et al., 2009; Lam et al., 2010; Sato et al., 2011; Daniel 
et al., 2012; Zhao et al., 2013). Some studies investigated the risk 
rate of PD in terms of osteopenia/osteoporosis/fracture (Sato 
et  al., 2001; Fink et  al., 2005, 2008; Latourelle et  al., 2010; Lee 
et  al., 2010). Others focused on the factors predisposing PD 
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patients to low BMD and factors improving osteoporosis (Lam 
et al., 2010): low percentage of body fat (Lam et al., 2010), low 
vitamin D, increased bone alkaline phosphatase (BALP) (Sato 
et  al., 2005a,b; Abou-Raya et  al., 2009), and sunlight exposure 
(Sato et  al., 1999, 2011), respectively, the relationship between 
the PD disease duration and osteopenia/osteoporosis(Daniel 
et al., 2012). Considering that the factors influencing BMD vary 
from different ethnicity to different country regions (Kao et al., 
1994; Torsney et al., 2014), it is very important to investigate the 
bone conditions in the mainland of China. From the PubMed 
searching, we found no BMD study from the mainland of China. 
This study first investigated the bone conditions of Chinese PD 
patients from Mainland China. It combined BMD, Ca–P product, 
and Hcy levels, S&E, Webster, UPDRS II, and UPDRS III scores, 
and H&Y stages to assess the changes in BMD and its potential 
roles in the progression and severity of Chinese PD patients. We 
used the S&E and Webster based on the following reasons: (1) 
Webster consists of 10 indexes for more details of PD symptoms 
and gave the direction that we should pay more attention to 
the MS such as the gait parameter and standing balance in the 
patients; (2) a combination of mutiple scales, including S&E, 
Webster, H&Y and the UPDRS, allowed us to explore the relation-
ship between the severity of PD and osteoporosis and to obtain 
more reliable results. Therefore, our data gained in this way may 
provide us with more persuasive and solid conclusion. From the 
Table 5, we note that the higher dose of l-DOPA usage and PD 
severity as indicated by S&E, Webster, UPDRS II, UPDRS III, and 
H&Y scores are negatively correlated to the BMD scores, strongly 
implying that as the disease develops, osteogenesis will be seri-
ously prevented and cause osteopenia. It indicates that the greater 
the severity of PD and the higher the dose of l-DOPA, the more 
serious the osteopenia with a decreased BMD, suggesting that 
the relationship of l-DOPA dosage with BMD changes may give 
insights into the safety of PD therapy. Ca and P are the main bone 
forming minerals. They affect the levels of PTH and are essential 
in bone formation and development. Previous studies suggested 
that ionized calcium (Sato et al., 2005a,b; Abou-Raya et al., 2009), 
25-hydroxyvitamin D (25-OHDA), and 1,25-dihydroxyvitamin 
D (1,25-[OH](2)D) (Sato et al., 2005a,b) have a close relationship 
with osteoporosis in PD patients. As Ca and P serum levels may 
TaBle 6 | comparisons of bone mineral density in PD patients at 
different stages of h&Y.
h&Y i and ii h&Y iii and iV P
Age 64.31 (6.63) 65.01 (9.26) 0.152
Duration (years) 3.25 (2.55) 4.12 (3.64) 0.232
LS 0.845 (0.11) 0.75 (0.10) 0.005**
LS T −1.94 (0.88) −3.01 (0.79) 0.003**
LS Z −0.74 (0.87) −1.93 (0.98) 0.002**
FN 0.69 (0.10) 0.61 (0.10) 0.027*
FN T −1.66 (0.70) −2.35 (0.78) 0.015*
FN Z −0.36 (0.59) −1.13 (0.67) 0.007**
Hip 0.86 (0.08) 0.77 (0.12) 0.004**
T −0.93 (0.46) −1.64 (0.61) 0.000***
Z −0.077 (0.56) −0.507 (0.55) 0.001**
*p < 0.05; **p < 0.01; ***p < 0.001 with Student’s test.
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be altered by some metabolism materials and can interact with 
each other, here we employed the Ca–P product to evaluate BMD 
in PD patients. When the Ca–P product is <35 mg2/dl2, the condi-
tions are not appropriate for calcification and may cause the bone 
salt to dissolve, preventing osteogenesis. As shown in Table  1, 
although the serum Ca and P levels were within the normal range, 
the Ca–P product in most of the PD patients (83.3%, Table 1) 
was <35 mg2/dl2, indicating that the majority of the PD patients’ 
bones were in a stage in which bone had a tendency to dissolve, 
with little osteogenesis.
Female steroid hormones may play an important role in osteo-
porosis, which affects approximately 30% of females and 8% of 
males who are over 50 years old (Kwan, 2015). Osteoporosis is 
not only associated with age but also with gender – females have 
a higher risk of osteoporosis. Individuals with PD also have a 
higher risk of osteoporosis, and gender is an independent factor 
in PD patients as well. In the current study, we aimed to explore 
the relationship between BMD and the symptom severity of PD 
patients according to gender.
As the optimal available method to predict future fracture, 
BMD is inversely correlated with fracture. There were major con-
troversies in some previous reviews and meta-analyses, mainly 
due to the difference in literature-searching criteria. For example, 
the meta-analysis by Torsney et al. used the following terms as 
the search strategy: “Osteoporosis and PD,” “Osteopenia and PD,” 
“Fracture and PD,” and “Bone health and PD” and showed that 
female patients were at greater risk of osteoporosis (Torsney et al., 
2014). However, a recent meta-analysis by Zhao et al. used differ-
ent search terms such as “Parkinson’s disease and osteoporosis” 
or “Parkinson’s disease and bone mineral density” and showed 
the opposite results, indicating that PD male patients to be at 
a higher risk for osteoporosis than female patients (Zhao et al., 
2013). Another main reason for this discrepancy may result from 
that fact that Zhao et al. chose different criteria, including the use 
of abstracts, non-English language articles and an article in which 
osteoporosis preceded the diagnosis of PD. These differences 
might account for the controversial evidences between the two 
meta-analyses (Zhao et al., 2013; Torsney et al., 2014).
In the current study, among the LS, FN, and hip, the LS was 
the most fragile, as its T-score was the lowest (Table 2), which 
explains why patients with PD have more than twice the risk for 
fractures than an age-matched cohort (Melton et al., 2006). In this 
study, we found that among the LS, FN, and hip, bone loss in the 
LS was the most severe in PD patients based on the T-scores. This 
finding is different from those of previous studies. Some studies 
from Western countries such as UK and Turkey show that the 
increased risks for osteoporosis or higher fracture risks in patients 
with PD normally occur in hip and proximal femur, respectively 
(Kamanli et al., 2008; Lyell et al., 2015). Bone loss was more severe 
in FN than lumber spine in PD patients from Egypt (Abou-Raya 
et al., 2009) and Korea (Song et al., 2009). In Japan, some studies 
showed that hip has a higher fracture risk in PD patients (Sato 
et al., 1999, 2001). Our findings have prompted us to pay more 
attention to osteoporosis in the LS in Chinese PD patients, unlike 
in those of other Asian countries or western countries.
Moreover, because the BMD of the female PD patients was 
lower than that of the male PD patients (Tables  3 and 4), we 
propose that being female was an independent risk factor for 
decreased bone density in PD patients. Several lines of evidence 
have shown that osteoporosis varies between men and women due 
to the uncoupling of bone remodeling as a result of sex hormone 
deficiencies, menopause, vitamin D deficiency, reduced synthesis 
of D hormone, and the lack of receptors or reduced receptor affin-
ity for D hormone in target organs (Liao et al., 2014).
We may see that BMD values were significantly different 
between males and females in normal people from Table  4. 
However, when comparing PD males to females, BMD values 
in the LS and FN showed no significant difference. When 
comparing BMD between PD patients and the controls by 
genders, there were significant differences in all of the BMD 
indexes between the PD males and the control males, but not 
all of them were significantly different between the female PD 
and female healthy subjects (Table 4). It seems that the BMD of 
both LS and FN in PD male and female patients becomes lower 
in comparison to healthy subjects, but the decrease is more 
pronounced in male PD patients, subsequently leading to the 
disappearance of differences between males and females with 
PD. We propose that BMD is more affected in PD males than in 
PD females, and the hip is probably less affected by osteoporosis 
in female PD patients compared to male PD patients. According 
to our findings (Table 4; Figure 2B), we hypothesize that the 
effect of genders on bone development may play an important 
role in PD patients.
Significant Spearman’s correlations were observed between 
BMD and the severity of PD, strongly indicating that the grade 
of osteoporosis may reflect the progression of PD. We therefore 
propose the following reasons for osteoporosis: (1) tremor, 
bradykinesia, and rigidity obviously decrease outdoor activi-
ties, including weight-bearing exercise, which may increase 
bone deposition and decrease bone re-absorption (Rison and 
Richardson, 2011); and (2) some NMS, such as depression and 
dementia, cause patients to be unwilling to participate in daily 
outdoor activities and to get less sunlight exposure (Rison and 
Richardson, 2011). This hypothesis is indirectly reflected in our 
results (Table  5). Furthermore, to obtain deeper insight into 
whether BMD levels vary according to the different stages of 
PD, we divided those PD subjects into two stages, H&Y I/II 
and III/IV, indicating the early and later stages, respectively, 
and compared BMD scores between these two stages. Our 
results (Table  6) further demonstrated that the osteoporosis 
in PD becomes worse in accordance with disease severity and 
progression.
Giving l-DOPA as a treatment can improve mobility and 
postural stability in PD; however, as the l-DOPA dosage 
increases, side effect such as dyskinesia may occur due to the 
high dose of l-DOPA. This could cause the patient to fall down 
more easily and aggravate the risk of fracture. According to 
the close relationship between PD and lower BMD, effective 
preventive strategies that enable PD patients to increase bone 
density, prevent excessive bone loss, and decrease the risk of 
falls are urgently needed. Treatment with bisphosphonates, 
vitamin D, and calcium can increase BMD and reduce fractures 
in PD patients. The l-DOPA-related adverse effects that are 
closely associated with falls and fracture mainly include two 
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aspects: (1) motor fluctuations and dyskinesias (Jankovic, 2005); 
and (2) hyperhomocysteinemia, which leads to an increase in 
the destruction of bone tissue, a decrease in BMD, and the 
development of osteopenia and osteoporosis (Rico et al., 1979; 
Bezsmertnyi Iu, 2013). It seems that bone loss in PD is multi-
factorial, including immobility, decreased muscle strength, low 
body weight, and vitamin D deficiency.
Several limitations of our study should be noted: (1) a small 
number of participants were recruited and it is necessary to 
conduct large population studies in the future; (2) there were no 
patients with PD at the late stage of the disease, as indicated by 
PD patients at H&Y from I to IV; (3) the daily intake of vitamin D 
and sunlight exposure were not considered in this study, and this 
study does not involve more assessment markers such as ionized 
Ca about bone formation and bone metabolism; and (4) in order 
to validate and complete the questionnaire, we only chose PD 
subjects with sufficient cognitive ability, significantly narrowing 
the population of the study. The limitations described above 
regarding the population chosen may have resulted in a bias for 
Ca, P, Hcy, and BMD levels in the PD. Thus, it is necessary to con-
duct larger population studies. However, this study still provides 
first and comprehensive data regarding the bone conditions of 
Chinese PD patients from Mainland China.
In summary, the current study supports the notion that PD 
patients have a higher risk for osteoporosis. In the healthy controls, 
female gender was an independent risk factor for osteoporosis. In 
addition, age could worsen bone loss and osteoporosis. Thus, our 
findings may provide a valuable hint for therapeutic strategy for 
treating osteoporosis in PD patients. Based on our findings, the 
examination of BMD using DXA is a valid way to detect osteo-
porosis in PD. Because of the prevalence of bone problems in PD, 
the therapeutic interventions should be initiated to improve the 
quality of life in PD.
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